Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™
18 juin 2019 06h00 HE
|
Zosano Pharma Corporation
Technical Transfer of manufacturing process to CMO signals commencement of commercial readiness activitiesNDA planned for Q4 2019 FREMONT, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- Zosano...
Zosano Pharma Reports First Quarter 2019 Financial Results
14 mai 2019 16h05 HE
|
Zosano Pharma Corporation
Multiple catalysts, including QtryptaTM NDA submission, anticipated in 2019Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM microneedle...
Zosano Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
09 mai 2019 09h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional...
Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update
08 mai 2019 16h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast...
Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain
16 avr. 2019 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed...
Zosano Announces Pricing of Public Offering of Common Stock
09 avr. 2019 09h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., April 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public...
Zosano Pharma Announces Proposed Public Offering of Common Stock
08 avr. 2019 16h01 HE
|
Zosano Pharma Corporation
FREMONT, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public...
Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference
11 mars 2019 16h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief...
Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update
07 mars 2019 16h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and...
Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta™ for the Acute Treatment of Migraine Disease
21 févr. 2019 06h00 HE
|
Zosano Pharma Corporation
Long-term one-year dosing reaffirmed well-tolerated safety profileQtrypta showed robust and rapid relief of migraine pain, an effect that was consistent throughout the chronic treatment periodNDA...